95 results about "Patient risk" patented technology

The invention discloses a clinical cerebral infarction patient recurrence risk early warning scoring visual model system. The system comprises an input module, an analysis module and a result output module. The invention also discloses an evaluation method of the clinical cerebral infarction patient recurrence risk early warning scoring visual model system. A clinical cerebral infarction patient recurrence risk evaluation nomogram is concise, popular and easy to understand and convenient for clinicians and patients to operate, and a current cerebral infarction recurrence risk of the patients is predicted. And meanwhile, high-risk, medium-risk and low-risk groups can be clearly distinguished according to patient risk scores calculated by a risk scoring formula in the model so that the clinicians are assisted to formulate an efficient treatment scheme. In the invention, a doctor and the patient are guided to evaluate early warning scores of the clinical cerebral infarction patient recurrence risk in combination with a statistical method, and patient data acquisition is verified through a corresponding mathematical statistical method so that the doctor and the patient can quickly grasp the clinical cerebral infarction patient recurrence risk and provide early warning information.

Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and / or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and / or serious side effects from anesthesia, analgesics, and / or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.

A graphical user interface provides a system and method for representing patient risks and other clinical information. The risks correspond to the probabilities that the patient exhibits particular conditions and respective etiologies. In addition the graphical user interface provides a method for representing the utility of different possibly harmful modes of physiologic monitoring in estimating these risks.

The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.

A system for assessing patient risk using open data and input of knowledge data, the system including a healthcare knowledge data input to receive open data and a knowledge input to accept input of knowledge data relating to risk; a healthcare risk engine to provide a healthcare risk knowledge graph from the open data and knowledge data by using input of risk-related terms to retrieve documents from the open data and by extracting the healthcare risk knowledge graph as entities from the documents corresponding to risk-related terms, as well as links between the entities. A patient risk graph prediction module predicts risks for a patient by combining information in a Patient Clinical Object (PCO) with entities in the healthcare risk knowledge graph to produce a patient risk graph.

The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin / CDK / RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.

Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and / or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight. Features of the devices include insertion transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. The devices have the capacity to vary in size and are desirably self-actuating in that they change shape and / or volume using internal motors or actuators. The changing character of the devices helps prevent the person's stomach from compensating for the implant, such as sometimes happens with static intragastric devices.

The present invention relates to a method of identification of clinically and genetically distinct sub-groups of patients subject to a medical condition, particularly breast, lung, and colon cancer patients using a composition of respective gene expression values for certain gene pairs. Sense-antisense gene pairs (SAGPs) which are relevant for a medical condition and the disease prognosis are used by the method to generate statistical models based on the expression values of the SAGPs. SAGPs for which the statistical models are found to have high value in prognosis of the variation of medical condition and the diseases are selected and integrated in the prognostic signature including specified parameters (e.g. cut-off values) of the prognostic model. It further relates to using respective gene expression values for these genes to predict patient′ risk groups (in context of patient's survival or / and disease progression) and to using the predicted groups for identification of patient risk, and specific and robust prognostic biomarkers with mechanistic interpretations of biological changes (associated with the gene signatures) appropriating for an implementation of therapeutic targeting.

A point of care diagnostic test, device and disposables for determining a patient risk for oral cancer in the same visit that a sample is collected.

A system and apparatus implementing a graphical user interface module for displaying information conveying a level of risk of delivery with shoulder dystocia associated to an obstetrics patient. The graphical user interface module displays a set of user modifiable information fields for allowing a user to enter a set of patient information data elements associated to the obstetrics patient. The graphical user interface module also displays a control allowing a user to cause the set of information data elements to be transmitted to a processing unit adapted to derive patient risk data at least in part on the basis of the set of information data elements, the patient risk data conveying a level of risk of delivery with shoulder dystocia. The graphical user interface module then displays the patient risk data with reference to risk assessment information.

The present invention reduces patient risks associated with RF-induced thermogenic tissue damage and with pulsed gradient-field-induced arrhythmias by using a defibrillator lead having a self-healing dielectric material that prevents induced voltages from MRI equipment from damaging an ICD or causing unintended defibrillation shocks to a patient. Another aspect of the present invention utilizes a sliding contact arrangement to prevent induced voltages from MRI equipment from being electrically coupled to an ICD thereby reducing patient risks associated with RF-induced thermogenic tissue damage and with pulsed gradient-field-induced arrhythmias.

A method of predicting an arrhythmia, such as ventricular tachycardia, for example, in a medical device using a quantitative measure in order to allow assessment of patient risk and to enable preventative interventions by the device and clinicians. The trending of day and night average heart rates, along with patient physical activity can be analyzed to provide prediction of impending arrhythmia within weeks. By examining day and night average heart rate for crossover points, where the night heart rate equals or exceeds the day rate, and monitoring for a concomitant elevation in the night heart rate from a reference value, specific days heralding an increased risk of arrhythmia can be determined and therapy can be updated accordingly.